2012-10-06 19:12:25 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Apnea - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Apnea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Apnea. Apnea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot

of the global therapeutic scenario for Apnea.
* A review of the Apnea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Apnea pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468457_apnea_pipeline_review_h2_2012.aspx


Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Apnea.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Apnea pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Apnea Overview
Therapeutics Development
An Overview of Pipeline Products for Apnea
Apnea Therapeutics under Development by Companies
Apnea Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Apnea Therapeutics - Products under Development by Companies
Apnea Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Apnea Therapeutics Development
Merck & Co., Inc.
VIVUS, Inc.
Cortex Pharmaceuticals, Inc.
Galleon Pharmaceuticals
Nobelpharma Co., Ltd.
Apnea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CX-1739 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Qsymia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-7288 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
orlistat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buspirone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
caffeine citrated - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide + Montelukast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
caffeine citrated - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
desogestrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
baclofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zopiclone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
caffeine citrated - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydroxycarbamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GAL-054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Apnea Therapeutics - Drug Profile Updates
Apnea Therapeutics - Discontinued Products
Apnea Therapeutics - Dormant Products
Apnea - Product Development Milestones
Featured News & Press Releases
Aug 10, 2012: Mylan Launches Generic Provigil Tablets
Jun 08, 2012: Mylan Settles Provigil Litigation With Teva
Apr 30, 2012: Teva Settles Nuvigil Litigation With Mylan
Apr 18, 2012: Teva To Present New Data On NUVIGIL At 2012 American Academy Of Neurology Annual Meeting
Apr 05, 2012: Mylan Sues FDA Seeking Ruling That Teva Holds No Exclusivity For Generic Version Of Provigil

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468457&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.